TABLE 2.
Mean Teff and SD, and Computed 95% CI, of Organs and Lesions for Commonly Applied Radiopharmaceuticals That Were Used in This Investigation
| Agent | Study | Reference | Patients (n) | Organ or target | Median | mean (h) | SD (h) | 95% CI (h) |
|---|---|---|---|---|---|---|---|---|
| 177Lu-DOTATATE | 1 | Hou et al. 2019 (12) | 30 (87) | Kidney* | 46 (30–82) | 47.0 | 11.6 | 28.5–73.6 |
| 2 | Heikkonen et al. 2016 (13) | 24 (24) | Kidney | NA (36–59) | 45.3 | 5.9 | 34.8–57.4 | |
| 3 | Hänscheid et al. 2018 (3)† | 27 (54) | Kidney‡ | 51 (40–68) | 51.0 | 7.0 | 38.8–66.0 | |
| 25 (25) | Liver‡ | 67 (55–117) | 76.5 | 15.5 | 51.4–110.7 | |||
| 27 (27) | Spleen‡ | 68 (52–99) | 68.0 | 11.8 | 49.5–91.6 | |||
| 22 (22) | Tumor‡ | 77 (56–130) | 85.4 | 18.5 | 56.0–125.8 | |||
| 4 | Del Prete et al. 2018 (11) | 158 (1,117) | Kidney* ‡ | 47 (23–159) | 50.8 | 16.9 | 25.6–91.0 | |
| Desy et al. 2020 (14) | 158 (474) | Bone marrow* ‡ | 70 (29–160) | 76.4 | 27.6 | 36.2–142.8 | ||
| 158 (2,166) | Tumor* ‡ | 84 (16–161) | 87.8 | 30.5 | 42.8–160.6 | |||
| 90Y-DOTATOC | 5 | Menda et al. 2018 (15) | 25 (69) | Kidney | NA (25–92) | 37.5 | 12.5 | 19.4–67.2 |
| 177Lu-PSMA-617 | 6 | Kurth et al. 2018 (16) | 25 (25) | Whole body | NA (22–86) | 40.5 | 15.8 | 18.8–79.1 |
| 7 | Sarnelli et al. 2019 (17) | 9 (9) | Parotid gland | 33 (26–61) | 35.4 | 10.6 | 22.2–53.2 | |
| 9 (9) | Kidney | 31 (12–81) | 39.2 | 20.9 | 17.2–76.2 | |||
| 9 (9) | Red marrow | 8 (3–15) | 8.0 | 4.7 | 3.2–16.3 | |||
| 9 (9) | Liver | 25 (13–63) | 33.5 | 20.0 | 13.4–69.1 | |||
| 9 (9) | Whole body | 40 (32–80) | 52.4 | 22.2 | 27.2–90.5 | |||
| 177Lu-PSMA-I&T | 8 | Written communications | 15 (290) | Bone metastases* | 38 (13–191) | 42.6 | 19.1 | 16.9–90.0 |
| 9 | Baum et al. 2016 (18) | 30 (NA) | Bone metastases‡ | 52 (14–149) | 52.0 | 30.0 | 16.2–132.6 | |
| 30 (NA) | Lymph nodemetastases‡ | 43 (25–160) | 43.0 | 32.0 | 9.9–132.7 | |||
| 30 (NA) | Kidney‡ | 33 (19–83) | 33.0 | 14.0 | 14.8–64.9 | |||
| 30 (NA) | Parotid gland‡ | 25 (20–43) | 25.0 | 5.0 | 16.7–36.1 |
*
Teff of each individual ROI (organ or lesion) was available (i.e., complete listing of Teff for all patients).
†
Overall dataset (29 patients) was primarily 177Lu-DOTATATE (22 patients) but also included 177Lu-DOTATOC (7 patients).
‡
Teff was published as median and range. For studies 3 and 9, corresponding mean and SD were calculated using method of Hozo et al. 2005 (19). For study 4, we had access to complete listing of Teff.
NA = not applicable.
Data in parentheses are range (for median) or total number of ROIs (for number of patients).